

# Toward Early Treatment of OA: Joggle Between Engineering and Medicine

# **Chaozong Liu**

Division of Surgery and Interventional Science
University College London
The Royal National Orthopaedic Hospital, Stanmore

E-mail: Chaozong.Liu@ucl.ac.uk



#### **Chronic Musculoskeletal Pain**
















Arthritis is one of the main chronic musculoskeletal disorders





#### Osteoarthritis – A Clinical Problem

(Osteoarthritis can affect every Joints)



- Results in chronic pain and loss of mobility.
- ✓ Prevalence of 18% in over 45 in England.
- ✓ Over 6.5 million Hip and knee OA cases reported in England alone (2012, Versus Arthritis).
- ✓ By 2050, 400 million people will suffer from OA worldwide, of whom 40 million will be severely disabled by the disease.
- OA is likely to increasing due to the aging of the population and increasing rates of obesity.









# Osteoarthritis – A Cartilage Problem

- Distribute joint loads over wide area
- Allow relative movement of joint with minimal friction and wear




- (1) Joint space narrowing
- (2) Osteophytes
- (3) Subchondral sclerosis
- (4) Subchondral cysts
- (5) Structural damage







# Osteoarthritis – A Cartilage Problem




#### Disruption of cartilage and it is non-reversible

- More diagnosed and treated more frequently in young athletes.
  - ✓ Pain
  - ✓ Swelling / Joint locking
  - ✓ Stiffness / Clicking

Reduce quality of life



# Osteoarthritis – Surgical Treatment




Joint replacements: Last resort in end-stage OA only when conservative management has failed:

- ✓ Non-reversible
- ✓ Big operation associated with lifetime complications
- ✓ Implant failures






# Implant Failure – An Unavoidable Problem





# Osteoarthritis – Early Interventions




Mid OA

Intervention of OA at every stage of progression




#### Translational in Practice at UCL/RNOH





Microfracture



- Autologous chondrocyte implantation (ACI) / MACI
- Bone Marrow Stem Cell Therapy




#### **OA - Material Scientist's View**






Femoral heads from total joint replacements: trauma and OA patients




Outerbridge Classification(Wright 2014)



pQCT to measure the volumetric BMD (vBMD, mg/cm3) (Stratec XCT 2000, Germany)



#### **OA - Material Scientist's View**








3.00


4.00

#### **OA - Material Scientist's View**










Positive association between local vBMD / bone remodelling and severity of cartilage







30 nm


#### **OA - Material Scientist's View**

#### **Subchondral bone Bulk composition (at.%)**


Info	О	Ca	С	P	Na	N	F	Mg
OA Bone	42.4±4.4	22.3±1.7	17.2±4.4	12.3±2.3	3.06±1.1	$2.64\pm0.7$	$0.20\pm0.1$	$0.03 \pm 0.02$
Normal	40.2	18.8	24.2	11.0	1.97	3.68	0.098	-









2D concentration contour map in the XY plane.








#### **OA - Material Scientist's View**





#### **OA - Material Scientist's View**




#### Concentration Volume Render of Ca


Hydroxyapatite crystals in OA bone are much bigger than that in non-OA samples, and in plate-like form.



Tidemark-Interface Between Cartilage and Subchondral Bone



 Advancing, irregular mineral tidemark could act like buried 'cheesegrater', damaging soft cartilage as joint articulates...






# Tidemark-Interface Between Cartilage and Subchondral Bone

Cartilage damage involving extrusion of mineralisable matrix HAC



## Paradigm for cartilage defect progression





#### "COWALK" with Clinicians

# Osteochondral scaffold Innovation for Early Repair of Cartilage Defect:


Delay or Avoid the Use of Joint Replacement



#### Translational in Practice at UCL/RNOH











# Bench to Bedside

#### **Scaffold - Control the Physical Environment**

- ✓ Large cartilage defects / osteochondral defects
- ✓ Recruit cells
- ✓ Support cells growth and differentiation.
- ✓ Simultaneously repair cartilage and bone





#### "COWALK" - Start with Materials

#### (Biomimetic Osteochondral Scaffold)

**EPSRC Feasibility Study 2014** 

#### **Gradient structure**





PLGA infiltrated collagen layer

**PLA Junction** 

Titanium matrix


- Structure gradient
- Mechanical property gradient
- Biological environment gradient




# "COWALK" - POC

(ARUK-IKC PoC Project (grant no: A1184))


- Titanium/PLA framework reinforced collagen osteochondral scaffold
- Trilayered Collagen / hydroxyapatite scaffold as control



The scaffold form a stable fixation in the bone




Scaffold was implanted in the sheep condyle



The control scaffold shrinked upon contact with blood and form an incomplete fill in the joint



(Innovate UK-MoST - 102872)



Scaffold was implanted in the sheep condyle



(Innovate UK-MoST - 102872)

Walk the sheep on a pressure pad: pre-surgery, 1 months, 6 months













- No pain and limping was observed
- Scaffold group returned to pre-op gait
- Addition of BMC does not seem to affect the gait significantly















(Innovate UK-MoST - 102872)










Analysed using: Fortier, Niederdauer, modified ICRS, ICRS and OAS systems

In Scaffold and Scaffold+BMC, we had over 92% cartilage fill




Cartilage Examinations - Macroscopic



(Innovate UK-MoST - 102872)


 Extensive bone ingrowth and integration in Ti layer, while fibrous tissue observed instead of bone in control






(Innovate UK-MoST - 102872)

 Consistently higher values of bone mineral density in scaffol groups compared to control groups







(Innovate UK-MoST - 102872)


#### Formation of hyaline-like cartilage in scaffold group

Alcian Blue Safranin-O Col-II Scaffold Control



#### "One Medicine" - For Human & Animal

- Late stage OA
- Unable to walk








18 Nov 2016

**L** 




## 12 Week post operation





### "One Medicine" - For Human & Animal

#### Collagen-II and Safranin-O staining - hyaline-like cartilage



Col-II Safranin-O
Cartilage biopsy post-2 years operation
Dog shoulder function is restored



# **COWALK - From Animals to Human**



CHESTERFIELD OFFICE
Copernan House,
St Mony's Court, St Many's Gote,
Dramonfield, Destrychir's Sci. 71D
LONDON OFFICE
44 Portioned Place,
London W78 1GH
e-0100 790 0400
artifefficiencesether.org

24 October 2017

Ref: KP/21875

Dr Chaozong Liu Royal National Orthopaedic Hospital Brockley Hill, Stanmore London HA7 4LP

Dear Dr Llu

#### Outline application for an Arthritis Research UK Priorities in Clinical Research award

Thank you for your application to the priorities in clinical research call entitled 'A first-irr-man study to assess short-term safety and efficacy of a novel osteochondral scaffold in early repair of cartilage defects'. Applications have now undergone review by the Arthritis Research UK Treatment Subcommittee. The purpose of the review is to identify at an early stage those proposals which the charity wish to invite to full application and those that will not be invited.

Outline applications were assessed on scientific quality, strategic relevance and remit, quality of the research design and feasibility of the work proposed.

I am pleased to inform you that after careful consideration the Treatment Subcommittee have recommended that your outline go through to a full application in this record.

The subcommittee were of the opinion that this was an exciting proposal with the potential to provide a novel intervention for a large number of patients and potentially provide good plue for money for the health services. The panel members were impressed by the significant outlent involvement in the development of the proposal and the plans described to disserminate the relation by committee of the study.



# First in man study


- > 20 Patients
- > RNOH
- > 01 Oct 2019 ~ 30 Sep 2023

The subcommittee were of the opinion that this was an exciting proposal with the potential to provide a novel intervention for a large number of patients and potentially provide good value for money for the health services. The panel members were impressed by the significant patient involvement in the development of the proposal and the plans described



# But there are problems.....

#### Translational Research in the UK – ONE CYCLE





# **Acknowledgement:**







# Innovate UK

Shenzhen Science and Technology **Innovation Commission** 深圳市科技创新委员会













Royal National Orthopaedic Hospital [17/17/55]





# Friends & Colleagues & Collaborators

